Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

The relationship between anogenital distance and fertility, and genome-wide associations for anogenital distance in Irish Holstein-Friesian cows.

Gobikrushanth M, Purfield DC, Kenneally J, Doyle RC, Holden SA, Martinez PM, Canadas ER, Bruinjé TC, Colazo MG, Ambrose DJ, Butler ST.

J Dairy Sci. 2019 Feb;102(2):1702-1711. doi: 10.3168/jds.2018-15552. Epub 2018 Dec 26.

PMID:
30594382
2.

Review: Applications and benefits of sexed semen in dairy and beef herds.

Holden SA, Butler ST.

Animal. 2018 Jun;12(s1):s97-s103. doi: 10.1017/S1751731118000721. Epub 2018 Apr 10. Review.

PMID:
29631644
3.

Effect of seminal plasma from high- and low-fertility bulls on cauda epididymal sperm function.

Holden SA, Fernandez-Fuertes B, Murphy EM, Lonergan P, Fair S.

Reprod Fertil Dev. 2017 Nov;29(12):2457-2465. doi: 10.1071/RD17136.

PMID:
28570851
4.

In vitro addition of docosahexaenoic acid improves the quality of cooled but not frozen-thawed stallion semen.

Silva DM, Holden SA, Lyons A, Souza JC, Fair S.

Reprod Fertil Dev. 2017 Sep;29(10):2021-2027. doi: 10.1071/RD16473.

PMID:
28171739
5.

Dietary polyunsaturated fatty acid supplementation of young post-pubertal dairy bulls alters the fatty acid composition of seminal plasma and spermatozoa but has no effect on semen volume or sperm quality.

Byrne CJ, Fair S, English AM, Holden SA, Dick JR, Lonergan P, Kenny DA.

Theriogenology. 2017 Mar 1;90:289-300. doi: 10.1016/j.theriogenology.2016.12.014. Epub 2016 Dec 18.

PMID:
28166982
6.

Relationship between in vitro sperm functional assessments, seminal plasma composition, and field fertility after AI with either non-sorted or sex-sorted bull semen.

Holden SA, Fernandez-Fuertes B, Murphy C, Whelan H, O'Gorman A, Brennan L, Butler ST, Lonergan P, Fair S.

Theriogenology. 2017 Jan 1;87:221-228. doi: 10.1016/j.theriogenology.2016.08.024. Epub 2016 Sep 3.

PMID:
27678515
7.

In vitro characterisation of fresh and frozen sex-sorted bull spermatozoa.

Holden SA, Murphy C, Moreno JF, Butler ST, Cromie AR, Lonergan P, Fair S.

Reprod Fertil Dev. 2017 Jul;29(7):1415-1425. doi: 10.1071/RD16086.

PMID:
27372889
8.

The impact of storage temperature and sperm number on the fertility of liquid-stored bull semen.

Murphy C, Holden SA, Murphy EM, Cromie AR, Lonergan P, Fair S.

Reprod Fertil Dev. 2015 Mar 5. doi: 10.1071/RD14369. [Epub ahead of print]

PMID:
25739711
9.

Cholesterol-loaded-cyclodextrins improve the post-thaw quality of stallion sperm.

Murphy C, English AM, Holden SA, Fair S.

Anim Reprod Sci. 2014 Mar;145(3-4):123-9. doi: 10.1016/j.anireprosci.2014.01.013. Epub 2014 Feb 6.

PMID:
24583046
10.

Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.

Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD.

Clin Cancer Res. 2001 Sep;7(9):2862-9.

11.

Differentiation and reversal of malignant changes in colon cancer through PPARgamma.

Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM.

Nat Med. 1998 Sep;4(9):1046-52.

PMID:
9734398
12.

Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.

Holden SA, Emi Y, Kakeji Y, Northey D, Teicher BA.

Cancer Chemother Pharmacol. 1997;40(1):87-93.

PMID:
9137536
13.

Efficient lipofection with cisplatin-resistant human tumor cells.

Huang L, Son K, Gao X, Hages D, Yang YY, Holden SA, Teicher B, Kirkwood J, Lazo JS.

Cancer Gene Ther. 1996 Mar-Apr;3(2):107-12.

PMID:
8729909
14.

Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.

Teicher BA, Holden SA, Goff DA, Wright JE, Tretyakov O, Ayash LJ.

Cancer Chemother Pharmacol. 1996;38(6):553-60.

PMID:
8823498
15.

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.

Teicher BA, Holden SA, Ara G, Korbut T, Menon K.

Cancer Chemother Pharmacol. 1996;38(2):169-77.

PMID:
8616908
16.

Transforming growth factor-beta in in vivo resistance.

Teicher BA, Holden SA, Ara G, Chen G.

Cancer Chemother Pharmacol. 1996;37(6):601-9.

PMID:
8612316
17.
18.

Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo.

Kusumoto T, Holden SA, Ara G, Teicher BA.

Int J Hyperthermia. 1995 Jul-Aug;11(4):575-86.

PMID:
7594810
19.

Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy.

Teicher BA, Holden SA, Ara G, Dupuis NP, Liu F, Yuan J, Ikebe M, Kakeji Y.

Int J Cancer. 1995 May 29;61(5):732-7.

PMID:
7768649
20.

Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing.

Teicher BA, Holden SA, Ara G, Dupuis NP, Goff D.

Cancer J Sci Am. 1995 May-Jun;1(1):43-8.

PMID:
9166453
21.

Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y, Goff D.

Breast Cancer Res Treat. 1995;36(2):227-36.

PMID:
8534870
22.

Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.

Holden SA, Teicher BA, Robinson MF, Northey D, Rosowsky A.

Cancer Chemother Pharmacol. 1995;36(2):165-71.

PMID:
7767954
23.

A preclinical model for sequential high-dose chemotherapy.

Holden SA, Teicher BA, Ayash LJ, Frei E 3rd.

Cancer Chemother Pharmacol. 1995;36(1):61-4.

PMID:
7720177
24.
25.
26.

Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo.

Teicher BA, Holden SA, Liu CJ, Ara G, Herman TS.

Cancer Lett. 1994 Jul 15;82(1):17-25.

PMID:
8033065
27.

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.

Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H.

Int J Cancer. 1994 Jun 15;57(6):920-5.

PMID:
7515861
28.

Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.

Teicher BA, Korbut TT, Menon K, Holden SA, Ara G.

Cancer Chemother Pharmacol. 1994;33(6):515-22.

PMID:
8137463
29.

In vivo modulation of several anticancer agents by beta-carotene.

Teicher BA, Schwartz JL, Holden SA, Ara G, Northey D.

Cancer Chemother Pharmacol. 1994;34(3):235-41.

PMID:
8004757
30.

Oxygenation of the rat 9L gliosarcoma and the rat 13672 mammary carcinoma with various doses of a hemoglobin solution.

Teicher BA, Holden SA, Dupuis NP, Kusomoto T, Liu M, Liu F, Menon K.

Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):827-33.

PMID:
7994406
31.

CAI: effects on cytotoxic therapies in vitro and in vivo.

Teicher BA, Holden SA, Chen YN, Ara G, Korbut TT, Northey D.

Cancer Chemother Pharmacol. 1994;34(6):515-21.

PMID:
7923563
32.

Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.

Teicher BA, Holden SA, Ara G, Northey D.

Anticancer Res. 1993 Nov-Dec;13(6A):2101-6.

PMID:
7507654
33.

A carbonic anhydrase inhibitor as a potential modulator of cancer therapies.

Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS.

Anticancer Res. 1993 Sep-Oct;13(5A):1549-56.

PMID:
8239534
34.

Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.

Teicher BA, Holden SA, Northey D, Dewhirst MW, Herman TS.

Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):103-9.

PMID:
8482616
35.

Intracellular distribution of various boron compounds for use in boron neutron capture therapy.

Nguyen T, Brownell GL, Holden SA, Teicher BA.

Biochem Pharmacol. 1993 Jan 7;45(1):147-55.

PMID:
8424808
37.

Subcellular distribution of various boron compounds and implications for their efficacy in boron neutron capture therapy by Monte Carlo simulations.

Nguyen T, Brownell GL, Holden SA, Kahl S, Miura M, Teicher BA.

Radiat Res. 1993 Jan;133(1):33-40.

PMID:
8434111
38.

Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.

Teicher BA, Holden SA, Khandakar V, Herman TS.

J Cancer Res Clin Oncol. 1993;119(11):645-51.

PMID:
8394365
39.

Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.

Teicher BA, Chatterjee D, Liu JT, Holden SA, Ara G.

Cancer Chemother Pharmacol. 1993;32(4):315-9.

PMID:
8324874
40.

Effect of hemoglobin solution on the response of intracranial and subcutaneous 9L tumors to antitumor alkylating agents.

Teicher BA, Holden SA, Menon K, Hopkins RE, Gawryl MS.

Cancer Chemother Pharmacol. 1993;33(1):57-62.

PMID:
8269590
41.

Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.

Frei E 3rd, Holden SA, Gonin R, Waxman DJ, Teicher BA.

Cancer Chemother Pharmacol. 1993;33(2):113-22.

PMID:
8261570
42.

Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Schwartz GN, Teicher BA, Eder JP Jr, Korbut T, Holden SA, Ara G, Herman TS.

Cancer Chemother Pharmacol. 1993;32(6):455-62.

PMID:
8258194
43.

Response of subpopulations of the FSall C fibrosarcoma to low dose x-rays and various potential enhancing agents.

Tanaka J, Holden SA, Herman TS, Teicher BA.

Anticancer Res. 1992 May-Jun;12(3):1029-33.

PMID:
1622113
44.

Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.

Holden SA, Teicher BA, Ara G, Herman TS, Coleman CN.

J Natl Cancer Inst. 1992 Feb 5;84(3):187-93.

PMID:
1542129
45.

A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.

Teicher BA, Holden SA, Ara G, Ha CS, Herman TS, Northey D.

J Cancer Res Clin Oncol. 1992;118(7):509-14.

PMID:
1624542
46.

Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.

Epelbaum R, Teicher BA, Holden SA, Ara G, Varshney A, Herman TS.

Eur J Cancer. 1992;28A(4-5):794-800.

PMID:
1524897
47.

Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.

Sotomayor EA, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, Frei E 3rd.

Cancer Chemother Pharmacol. 1992;30(5):377-84.

PMID:
1505076
48.

Enhancement by perflusion emulsion (Oxygent) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents.

Holden SA, Teicher BA, Ha C, Ara G, Herman TS.

Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):895-8.

PMID:
1391529
49.

Effect of a bovine hemoglobin preparation (SBHS) on the response of two murine solid tumors to radiation therapy or chemotherapeutic alkylating agents.

Teicher BA, Holden SA, Ara G, Herman TS, Hopkins RE, Menon K.

Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):657-60.

PMID:
1391491
50.

Effect of environmental conditions (pH, oxygenation and temperature) on the cytotoxicity of flavone acetic acid and its dimethylaminoethyl ester.

Teicher BA, Holden SA, Rudolph MB, Sotomayor EA, Herman TS.

Int J Hyperthermia. 1991 Nov-Dec;7(6):905-15.

PMID:
1806644

Supplemental Content

Loading ...
Support Center